See All Slides - tctmd.com

Slides

Presentation TCT 2013

MRI Catheterization: Ready for Primetime?

Presenter: Robert Lederman

October 31, 2013

Presentation TCT 2013

Genetic Testing for 9p21 can Cost Effectively Reduce Cardiovascular Events

Presenter: James Devlin

October 31, 2013

Presentation TCT 2013

Case #3: Left Main + Ostial LAD (Medina 1,1,0)

Presenter: Jeffrey Moses

October 31, 2013

Presentation TCT 2013

Vascular Intervention Highlights (from Aneurysms to Critical Limb Ischemia): Achievements, Challenges, and Future Directions

Presenter: Barry Katzen

October 31, 2013

Presentation TCT 2013

Impact of Lesion Complexity on Outcomes in Drug-Coated Balloon Trials: Implications for Device Selection and Future Trial Design

Presenter: Gunnar Tepe

October 31, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

How Did I Treat this Patient?(6)

Presenter: Vjekoslav Tomulic

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

Presentation TCT 2013

The Revolution of Interventional Innovation: The Soul of ALL Current and Future Catheter-Based Therapies

Presenter: Peter Fitzgerald

October 31, 2013

Presentation TCT 2013

Coronary Drug-Coated Balloons in De Novo Lesions: What are the Technical and Safety Considerations That Haven't Been Addressed?

Presenter: Bernardo Cortese

October 31, 2013

Advertisement

Slides

MRI Catheterization: Ready for Primetime?

Genetic Testing for 9p21 can Cost Effectively Reduce Cardiovascular Events

Case #3: Left Main + Ostial LAD (Medina 1,1,0)

Vascular Intervention Highlights (from Aneurysms to Critical Limb Ischemia): Achievements, Challenges, and Future Directions

Impact of Lesion Complexity on Outcomes in Drug-Coated Balloon Trials: Implications for Device Selection and Future Trial Design

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

How Did I Treat this Patient?(6)

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

The Revolution of Interventional Innovation: The Soul of ALL Current and Future Catheter-Based Therapies

Coronary Drug-Coated Balloons in De Novo Lesions: What are the Technical and Safety Considerations That Haven't Been Addressed?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content